JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Hologic Inc

Suletud

SektorTervishoid

67.97 -0.21

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

67.39

Max

68.37

Põhinäitajad

By Trading Economics

Sissetulek

212M

195M

Müük

19M

1B

P/E

Sektori keskmine

28.178

34.393

Aktsiakasum

1.08

Kasumimarginaal

19.037

Töötajad

7,063

EBITDA

262M

255M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+8.29% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

3. nov 2025

Turustatistika

By TradingEconomics

Turukapital

468M

15B

Eelmine avamishind

68.18

Eelmine sulgemishind

67.97

Uudiste sentiment

By Acuity

24%

76%

45 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Hologic Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. mai 2025, 18:46 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone

27. mai 2025, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27. mai 2025, 19:06 UTC

Omandamised, ülevõtmised, äriostud

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27. mai 2025, 18:26 UTC

Omandamised, ülevõtmised, äriostud

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 19%. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Hologic Inc Prognoos

Hinnasiht

By TipRanks

8.29% tõus

12 kuu keskmine prognoos

Keskmine 73.7 USD  8.29%

Kõrge 87 USD

Madal 69 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Hologic Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

14 ratings

7

Osta

7

Hoia

0

Müü

Tehniline skoor

By Trading Central

52.69 / 58.605Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

45 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.